The clinical significance of BRAF V600E in multiple myeloma has been characterized in one study.8 Seven myeloma patients with BRAF V600E had significantly shorter OS (45 versus 105 months) and increased incidence of extra medullary disease (EMD; 57% versus 17%) compared with 251 patients with wild-type (wt) BRAF. This evidence concerns the gene BRAF and AL amyloidosis.